「elecoglipron」と呼ばれる新しい経口投与型の実験薬が、第2b相試験において2型糖尿病患者の血糖コントロール改善および体重減少に寄与したことが明らかになった。SOLSTICE試験の結果は、米国糖尿病学会の学術集会で発表され、『ランセット』誌に掲載された。
アストラゼネカが支援したこの臨床試験には、9カ国で406人の成人が参加した。参加者は、非ペプチド性GLP-1受容体作動薬であるelecoglipronの異なる用量、またはプラセボを26週間にわたって投与された。薬を投与されたグループでは、最大89.6％がHbA1c値を7％未満に抑えることができた一方、プラセボ群では24.9％にとどまった。また、最大72.3％が5％以上の体重減少を達成し、プラセボ群の20.2％を上回った。本試験の発表者であり、マス・ジェネラル・ブリガムで糖尿病臨床研究のディレクターを務めるバニータ・アローダ氏は、今回の知見は、現行の注射剤やペプチド系薬剤の限界を克服する経口GLP-1療法の可能性を示すものだと述べた。なお、安全性プロファイルはこのクラスの他の薬剤と同等であった。
AIによるレポート AIによって生成された画像 事実確認済み
A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.
A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.
AIによるレポート
Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.
The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.
AIによるレポート
Researchers from Mass General Brigham found that the cholesterol drug evolocumab cuts the risk of first-time major cardiovascular events by 31% in high-risk patients with diabetes who lack diagnosed atherosclerosis. The results, from a subgroup analysis of the VESALIUS-CV trial, were presented at the American College of Cardiology's Annual Scientific Session and published in JAMA. Patients on the drug saw LDL cholesterol levels drop significantly alongside standard treatments.
An experimental therapy called VERVE-102 lowered LDL cholesterol by up to 62 percent after a single dose in an early safety study. The results come from a Phase I trial involving 35 patients with high cholesterol or early cardiovascular disease. Data were published this week in the New England Journal of Medicine.
AIによるレポート
A Brazilian study found that fish oil supplements reduced insulin resistance and inflammation in rats modeling non-obese type 2 diabetes. The research highlights a potential role for omega-3 fatty acids in cases where obesity is not a factor.